Gaceta Médica de México

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Gaceta Médica de México >Year 2008, Issue 6

Peña-Rodríguez JC
II.Daño renal y riesgo de enfermedad cardiovascular
Gac Med Mex 2008; 144 (6)

Language: Español
References: 11
Page: 513-516
PDF: 49.50 Kb.

Full text


Cardiovascular complications are the main cause of death (50%) in patients with chronic renal failure. In this review is analyzed and discussed the traditional a non traditional causes of cardiovascular damage, in patients with chronic renal failure. Some but not all of the factors involved were dissected and analyzed. The hemodynamic factors such as: left ventricular hyperthrophy eccentric and concentric and dilated cardiomyopathy were described. To these hemodynamic factors were added non traditional factors such as: anemia, elevated PTH, alterations in K+, Ca++ and Mg++, serum phosphate above 6mg/dl, increased PCR and cardiac troponine T plasma values, accumulation of asimetric dimethyl arginine (ADMA) a blocker of nitric oxide sinthase and endothelial disfunction. All these factors produced left ventricular hyperthrophy, arterial stiffness, peripheral vascular disease, coronary disease, myocardial infarction, heart failure and in some cases sudden death. It is also summarized the main treatments of the cardiovascular complications.

Key words: Cardiovascular damage, renal failure, traditional factors, non traditional factors.


  1. US Renal Data System. USRDS Annual Data Report: Atlas of end stage renal disease in the United States. USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.

  2. Muntner P, He J, Hamm L, Loria C, Whelton PK, et al. J Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-753.

  3. Anavekar NS, McMurray JJ, Velázquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal disfunction and cardiovascular outcome after myocardial infarction. N Engl J Med 2004;351:1258-1295.

  4. Foley RN. Epidemiology of cardiovascular disease in chronic renal failure. J Am Soc Nephrol 1998;9:S16-S23.

  5. Aoki J, Ikari Y, Nakajima H, Sugimoto T, Hatori M, Tanimoto S, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005;67:333-340.

  6. Vasan RS, Levy D. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 2006;101:2118-2121.

  7. Zocalli C. Asymmetric dimethylarginine in end stage renal disease patients: A biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney Int 2006;70:2053-2055.

  8. Aslam S, Santha T, Leone A , Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end stage renal disease patients in hemodialysis. Kidney Int 2006;70:2109-2115.

  9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. Am J Kidney Dis 1998;31:607-617.

  10. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary artery calcification in young adults with end stage renal disease who are undergoing hemodialysis. N Engl J Med 2000; 342:1478-1483.

  11. Giachelli CM. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14:S300-S304.

>Journals >Gaceta Médica de México >Year 2008, Issue 6

· Journal Index 
· Links 

Copyright 2019